Physician profile
David S Bechtel
NPI 1427091560
$3,413.65
in general payments reported to CMS, 2019-2025
28 companies · $604 in 2025
The $604 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $499 · 2020: $249 · 2021: $439 · 2022: $274 · 2023: $673 · 2024: $676 · 2025: $604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,953.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,953.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $583.51 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $356.98 | 2019-2025 | |
| Glaxosmithkline, LLC. | $313.71 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $267.31 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $264.23 | 2021-2025 | Ubrelvy, Vraylar |
| Merck Sharp & Dohme LLC | $256.31 | 2019-2025 | Capvaxive, Pneumovax 23, Vaxneuvance |
| Astellas Pharma US INC | $241.60 | 2019-2024 | Veozah, Myrbetriq |
| Novo Nordisk INC | $198.22 | 2019-2025 | Wegovy |
| Exact Sciences Corporation | $188.53 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amarin Pharma, INC. | $157.60 | 2019-2021 | |
| Corcept Therapeutics | $93.07 | 2025 | Korlym |
| Janssen Pharmaceuticals, INC | $86.09 | 2024-2025 | Spravato |
| Inspire Medical Systems, INC. | $76.93 | 2023-2024 | Inspire |
| Amgen INC. | $68.24 | 2020-2024 | Evenity |
| Biohaven Pharmaceutical Holding Company LTD. | $30.18 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $27.69 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.48 | 2019 | |
| Sanofi Pasteur INC. | $25.43 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $24.77 | 2025 | |
| Lundbeck LLC | $18.21 | 2024 | Vyepti |
| Nalpropion Pharmaceuticals LLC | $14.81 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $14.81 | 2021 | |
| Azurity Pharmaceuticals, INC. | $14.17 | 2023 | Adthyza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.79 | 2024 | Xifaxan |
| Seqirus USA INC | $13.57 | 2022 | |
| Alexion Pharmaceuticals, INC. | $13.28 | 2019 | |
| Allergan, INC. | $13.15 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $11.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Bechtel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.